Global Innovative Platforms Inc. is engaged in the business of testing breath to detect and assist in the treatment of disease. The company focuses on advancing animal health through breath analysis and air quality technology. It develops non‑invasive diagnostic tools such as the VOCAM Plus and the FROG, which combine gas chromatography with artificial‑intelligence software to analyse volatile organic compounds in breath and environmental samples. The VOCAM Plus unit processes breath samples using a proprietary gas chromatograph capable of detecting parts per trillion concentrations, while the FROG unit incorporates a collection wand for testing feed, water, soil and air. Its proprietary AI software, named Ellvin, interprets the chromatographic data and displays results on a smart device via Bluetooth or 5G connection. The company’s mission is to revolutionise early detection of a wide array of animal‑related abnormalities, beginning with a breath test for heartworm in dogs, and to expand the platform to detect multiple diseases from a single sample.

The company generates revenue from the sale of its VOCAM Plus and FROG devices, associated consumables, and related analytical services. Although it recorded no revenue for the fiscal years ended September 30, 2024 and September 30, 2025, it has billed and collected $85,000 subsequent to September 30, 2025 from early access programs and pilot studies. Revenue is expected to arise from direct sales to veterinary clinics, research laboratories and animal‑health customers, as well as from licensing arrangements for its technology. The firm anticipates a per‑use cost below one dollar once the hardware and consumables are produced at scale, which should support recurring revenue from repeat testing and service contracts.

Within the animal‑health diagnostics market, Global Innovative Platforms Inc. positions itself as a pioneer in breath‑based testing, competing against established blood‑test providers such as IDEXX Laboratories, Antech Diagnostics and Zoetis. Its competitive advantages include the ability to detect heartworm earlier than the six‑month threshold of current antigen tests, a non‑invasive sampling process that eliminates the need for needles, quantitative data that enables monitoring of treatment response, and a cost‑effective platform with projected per‑use costs below one dollar. The company also benefits from proprietary artificial‑intelligence software that continuously improves with additional data, allowing the platform to expand to multiple diseases from a single breath sample. Management notes that there are no other significant companies focused on animal breathomics, which leaves a relatively open field for its technology. The addressable market for heartworm testing alone is estimated at approximately ten million tests per year in the United States, with each test priced between $30 and $50, indicating a sizable opportunity for a lower‑cost alternative.

The company’s customers are veterinary clinics, animal hospitals, research institutions and livestock producers that require diagnostic testing for companion and production animals. While the filing does not disclose specific customer names, it indicates that the target market includes the approximately ten million dogs tested for heartworm annually in the United States and analogous segments in other animal‑health sectors such as cattle, swine and poultry operations. The platform is also designed to serve research organizations engaged in epidemiological studies and pharmaceutical companies developing veterinary therapeutics, as well as farms seeking to monitor herd health through environmental sampling of feed, water and air.